After meeting with FDA officials about its E5 anti-endotoxin monoclonal antibody, Xoma Corp. said Thursday that it will submit additional data and analyses from the two completed randomized, multicenter, placebo-controlled E5 studies.

The company announced June 4 that the FDA might request additional clinical testing of E5 to support Xoma's product license application, a move that sent Xoma's stock (NASDAQ:XOMA) down. The Berkeley, Calif., company hopes that the additional information it plans to submit will prove sufficient. A company spokeswoman declined to speculate Thursday on when the FDA might decide the issue.

(c) 1997 American Health Consultants. All rights reserved.